DNDi has various types of agreements with its partners worldwide, such as Research Services Agreements, Material Transfer Agreements, Research and License Agreements, Collaboration Agreements, Clinical Trial Agreements, Financial Agreements, etc.

Research Services Agreements regulate contractual relationship between research service providers and DNDi. Material Transfer Agreements provide access to compounds for testing. In addition to these agreements, DNDi seeks to conclude Research and License Agreements with key partners which involve a greater commitment from both parties. The core of these agreements concern IP ownership (generally owned by the partner and in some cases co-owned), and licensing clauses. Several conditions are required to ensure availability and affordability of the treatment and respect of DNDi’s IP policy objectives. As a not-for-profit and patient-needs driven organization, DNDi seeks transparency to efficiently address urgent patient needs. Therefore, the licenses should be:

  • Royalty-free to ensure the lowest possible price
  • Sub-licensable, or in other terms, contain the authorization to disclose the obtained information to another party in order to continue product development
  • Worldwide coverage both for R&D and for manufacture
  • Non-exclusive to enable third parties to enter the field (included in our most innovative agreements)

An important objective for DNDi’s agreement is limited confidentiality – to make available all information generated on the product during its development in the form of publications or databases.

 

Pharmaceuticals

AbbVie (USA) – Projects: Screening filarial diseases / Screening Chagas / Screening leishmaniasisLeish H2L / Chagas H2L  / Booster H2L (leishmaniasis) / Booster H2L (Chagas) / Leish L205 Series / AminopyrazolesChagas C205 Series / Flubendazole Macrofilaricide / AbbV4083 / ‘4-in-1’ LPV/r/ABC/3TC

Astellas Pharma Inc. (Japan) – Projects: Screening Chagas / Screening leishmaniasis

AstraZeneca (UK, Sweden) – Projects: Screening Chagas / Screening leishmaniasis / Leish H2L / Chagas H2L / Booster H2L (leishmaniasis) / Booster H2L (Chagas)

Avista Pharma (formerly SCYNEXIS Inc) (USA) – Projects: Acoziborole / SCYX-1330682 SCYX-1608210 / DNDi-5421 DNDi 5610 /  SCYX-2035811 / DNDi-6148

Bayer Healthcare (Germany) – Projects: Screening Chagas / Screening leishmaniasis / Emodepside

Boehringer Ingelheim, Animal Health Business Unit (formerly Sanofi Merial) (USA) – Projects: Screening filarial diseases / Screening Chagas / Screening leishmaniasis

Bristol-Myers Squibb (USA) – Projects: Screening Chagas / Screening leishmaniasis

Cipla Ltd. (India) – Projects: ‘4-in-1’ LPV/r/ABC/3TC / LPV/r pellets with dual NRTI / ASMQ

Daiichi Sankyo (Japan) – Projects: Screening Chagas / Screening leishmaniasis / Daiichi Sankyo LH2L / Daiichi Sankyo CH2L

Daiichi Sankyo RD Novare Co., Ltd. (Japan) – Projects: Screening Chagas / Screening leishmaniasis

Debiopharm (Switzerland) – Projects: Screening

 DuPont (formerly E.I du Pont Nemours) (USA) – Projects: Screening Chagas / Screening leishmaniasis

Eisai Co., Ltd. (Japan) – Projects: Screening Chagas / Screening leishmaniasis /  Leish H2L / Chagas H2L / Booster H2L (leishmaniasis) / Booster H2L (Chagas)Azoles E1224New benz regimens +/- fosravuconazole / Fosravuconazole

Eurofins Optimed (France) – Projects: Fexinidazole-Miltefosine combination

Farmanguinhos (Fiocruz) (Brazil) – Projects: ASMQ

GeneDesign Inc. (Japan) – Projects: CpG-D35

Gilead Sciences (USA) – Projects: Fexinidazole (HAT) 

GlaxoSmithKline (GSK) (Spain, UK) – Projects: Screening filarial diseasesScreening Chagas / Screening leishmaniasis / Leish H2L / Chagas H2L GSK3186899/DDD853651 & GSK3494245/DDD1305143 / New treatments for HIV/VL 

Genomics Institute of the Novartis Research Foundation (GNF Novartis), Genomics Institute of the Novartis Research Foundation (USA) – Projects: Screening

Humax Pharmaceutical (Colombia) – Projects: Anfoleish

INSUD PHARMA (Argentina) – Projects: Ravidasvir/ Sofosbuvir

Johnson & Johnson (USA) – Projects: Screening filarial diseases / Screening Chagas / Screening leishmaniasis / Flubendazole Macrofilaricide

Janssen (Belgium) – Projects: Screening

Janssen Research & Development (USA) – Projects: Flubendazole Macrofilaricide

KAVI-Bio-Zeq (Kenya) – Projects: Miltefosine-Paromomycin combination for Africa

 Laboratorio ELEA PHOENIX (Argentina) – Projects: New benz regimens +/- fosravuconazole / Paediatric dosage form of benznidazole / Ravidasvir/ Sofosbuvir

LAFEPE (Brazil) – Projects: Paediatric dosage form of benznidazole

Mercachem (The Netherlands) – Projects: Screening

Merck (USA) – Projects: Screening filarial disease / Screening Chagas / Screening leishmaniasis / Leish H2L / Chagas H2L

Merck KGaA (Germany) – Projects: Screening / Booster H2L (leishmaniasis) / Booster H2L (Chagas) 

Paladin Labs (Canada) – Projects: VL-0208

Pharco Pharmaceuticals Inc. (Egypt) – Projects: Ravidasvir/ Sofosbuvir

Pharmaniaga (Malaysia) – Projects: Ravidasvir/ Sofosbuvir

Pfizer Ltd. (formerly Anacor Pharmaceuticals) (USA) – Projects: Screening Chagas / Screening leishmaniasis / Aminopyrazoles / SCYX-1330682 SCYX-1608210 / Leish H2L / DNDi-5421 DNDi-5610 / Acoziborole / DNDi-6148 / Oxachagas 

Presidio Pharmaceuticals, Inc. (USA) – Projects: Ravidasvir/Sofosbuvir

Sanofi (France) – Projects: Screening Chagas / Screening leishmaniasis / Leish H2L / Chagas H2LASAQ / Fexinidazole (HAT) New treatments for HIV/VL 

Sanofi-Chinoin (Hungary) – Projects: Fexinidazole-Miltefosine combination

Sara Pharm (Romania) – Projects: DNDi-6148

Shionogi & Co., Ldt. (Japan) – Projects: Screening Chagas / Screening leishmaniasis / Leish H2L / Chagas H2L / Booster H2L (leishmaniasis) / Booster H2L (Chagas) 

Syngene (India) – Projects: DNDi-6148 / DNDi-0690

Takeda Pharmaceutical Company Ltd. (Japan) – Projects: Screening Chagas / Screening leishmaniasis / Aminopyrazoles /  Leish H2L / Chagas H2L / Booster H2L (leishmaniasis) / Booster H2L (Chagas)DNDi-5561

Zenufa Laboratories Ltd (Tanzania) – Projects: ASAQ

 Zoetis (formerly Pfizer Animal Health) (USA) – Projects: Screening Chagas / Screening leishmaniasis

top of the page

 

Biotechs

 Abzena (formerly Polytherics) (UK) – Projects: Formulation of amphotericin B, in collaboration with Imperial College.

 BioAscent (UK) – Projects: Screening Chagas / Screening leishmaniasis / Leish L205 series

Celgene Corporation (USA) – Projects: Screening filarial diseaseScreening Chagas / Screening leishmaniasis / CGH VL series 1 / Booster H2L (leishmaniasis) / Booster H2L (Chagas)Macro filaricide 3

Evolva (Switzerland) – Projects: Screening

 iThemba Labs (South Africa) – Projects: Lead optimization

 Sanofi Genzyme (formerly Genzyme) (USA) – Projects: Material transfer for research and development on HAT, Chagas disease, and leishmaniasis.

Sequella, Inc. (USA) – Projects: Screening Chagas / Screening leishmaniasis

 Thermosurgery Technologies Inc. (USA) – Projects: New CL combination therapies

Vertex (USA) – Projects: Screening

top of the page

 

Universities

Addis Ababa University (Ethiopia) – Projects: VL-0208New treatments for HIV/VL / SSG&PM

 Chiang Mai University, Associated Medical Sciences/PHPT International Research Unit (Thailand) – Projects: LPV/r pellets with dual NRTI /  Ravidasvir/Sofosbuvir

Banaras Hindu University, Institute of Medical Sciences (India) – Projects: New treatments for PKDL

Baylor College of Medicine Children’s Foundation (Uganda) – Projects: LPV/r pellets with dual NRTI

Centres d’Investigation Clinique des Centres Hospitaliers Universitaires de Clermont-Ferrand (France) – Projects: Fexinidazole-Miltefosine combination

Free University Amsterdam (The Netherlands) – Projects: Fosravuconazole

Fundacao de Apoio Universidade Federale de Sao Paolo (FapUnifesp) (Brazil) – Projects: Leish H2L / Chagas H2L

Gondar University Hospital (Ethiopia) – Projects: VL-0208 / Miltefosine-Paromomycin combination for AfricaNew treatments for HIV/VL / SSG&PM 

 Griffith University, Griffith Institute for Drug Discovery (GRIDD) (formerly Eskitis Institute for Cell and Molecular Therapies) (Australia) – Projects: Screening Chagas / Screening leishmaniasis / Leish H2L / Chagas H2L / Chagas C205 series / Leish L205 series

Imperial College London (UK) – Projects: Formulation of amphotericin B with Polytherics / Emodepside

 Liverpool School of Hygiene and Tropical Medicine (LSTM) (UK) – Projects: ABBV-4083

London School of Hygiene and Tropical Medicine (UK) – Projects: Screening Chagas / Screening leishmaniasis / Aminopyrazoles / VL-0208 / VL-2098DNDi-5421 DNDi-5610 / CGH VL series 1Leish H2L / DNDi-6148 / DNDi-0690 / Fexinidazole-Miltefosine combination / New treatments for HIV/VL / SSG&PM / New VL treatments Asia / Nitroimidazole / OxachagasChagas H2L / Biomarkers /  Chagas C205 series / Leish L205 series

Mahidol UniversityShoklo Malaria Research Unit (SMRU) (Thailand) – Projects: ASMQ / ASAQ / Emodepside

Makarere University (Uganda) – Projects: Fexinidazole-Miltefosine combination / SSG&PM / VL-0208 / Miltefosine-Paromomycin combination for Africa

McGill University (Canada) – Projects: Biomarkers / Flubendazole Macrofilaricide

Michigan State University (USA) – Projects: Flubendazole Macrofilaricide

Monash University, Centre for Drug Candidate Optimization (Australia) – Projects: Fenarimol / Chagas H2L / Leish H2L / Chagas C205 series / Aminopyrazoles

Murdoch University, School of Veterinary and Biomedical Science (Australia) – Projects: Fenarimol series (Chagas) / Nitroimidazole (Chagas)

Nagasaki University (Japan) – Projects: CpG-D35

Ohio State University (USA) – Projects: CpG-D35

 Osaka University (Japan) – Projects: CpG-D35

Pace University (USA) – Projects: SCYX-2035811 / SCYX-1330682 SCYX-1608210

Radboud University Medical Center (The Netherlands) – Projects: Fosravuconazole

Stellenbosch University (South Africa) – Projects: Superbooster therapy paediatric HIV/TB

 UCL School of Pharmacy (formerly London School of Pharmacy) (UK) – Projects: Formulation of amphotericin B, in collaboration with Imperial College.

Universidad Autónoma Juan Misael Saracho (Bolivia) – Projects: Biomarkers / Azoles E1224New benz regimens +/- fosravuconazole regimens / Fexinidazole (Chagas)

 Universidade de Brasilia (Brazil) – Projects: New VL treatments Latin America

Universidade Estadual de Campinas UNICAMP, Instituto de Química (Brazil) – Project: Leish H2L / Chagas H2L

Universidade Estadual de Montes Claros (Brazil) – Projects: New VL treatments Latin America

Universidade Federal de Ouro Preto (Brazil) – Projects: Fenarimol / Nitroimidazole

 Universidade Federal de Piauí (Brazil) – Projects: New VL treatments Latin America

 Universidade Federal de Sergipe (Brazil) – Projects: New VL treatments Latin America

Universidad Mayor de San Simon (Bolivia) – Projects: Biomarkers / Azoles E1224New benz regimens +/- fosravuconazole regimens / Fexinidazole (Chagas)

Universidad Peruana Cayetano Heredia, Instituto de Medicina Tropical Alexander von Humboldt (Peru) – Projects: New CL combination therapies

Universidad Nacional de San Martin (Argentina) – Projects: Biomarkers 

 Universidad São Paolo (USP), Instituto de Física (Brazil) – Projects: Chagas H2L / Leish H2L

Universidade do Estado do Rio de Janeiro (Brazil) – Projects: New VL treatments Latin America

Université de Bordeaux, Faculté de Pharmacie (France) – Projects: ASAQ

University de Antioquia, Programa de Estudio y Control de Enfermedades Tropiales (PECET) (Colombia) – Projects: Anfoleish / New CL combination therapies

 University Hospital of Bonn, Institute of Medical Microbiology, Immunology and Parasitology (Germany) – Projects: Screening filarial diseases / Macro Filaricide 3 ABBV-4083 / Oxfendazole

University of Antwerp, Laboratory of Microbiology, Parasitology and Hygiene (Belgium) – Projects: Screening Chagas / Screening leishmaniasis / Leish H2L / Chagas H2L / SCYX-1330682 SCYX-1608210 / DNDi-5421 DNDi-5610 / Aminopyrazoles / DNDi-6148 / DNDi-0690VL-0208 / CGH VL series 1  / Nitroimidazole / OxachagasLeish L205 series

 University of Auckland (New Zealand) – Projects: SCYX-2035811 / Nitroimidazole / DNDi-0690

 University of Buea (Cameroon) – Projects: Flubendazole Macrofilaricide

 University of California (UCSF) (USA) – Projects: K777Superbooster therapy Paediatric HIV/TB

University of Cape Town (UCT), Division of Clinical Pharmacology Department of Medicine (South Africa) – Projects: Screening Chagas / Screening leishmaniasis / Superbooster therapy paediatric HIV/TB

University of Dundee, Drug Discovery Unit (UK) – Projects: Screening Chagas / Screening leishmaniasis / Leish H2L / Chagas H2L / GSK3186899/DDD853651 & GSK3494245/DDD1305143DNDI-0690

University of Gedaraf (Sudan) – Projects: New treatments for PKDL

University of Health and Allied Sciences (Ghana) – Projects: Emodepside

University of Nairobi (Kenya) – Projects: LPV/r pellets with dual NRTI

University of North Carolina, Office of Technology Development (USA) – Projects: Screening filarial diseases

University of Oxford, Infectious Diseases Data Observatory (IDDO), Worldwide Antimalarial Drug Resistance Network (UK) – Projects: ASAQ / ASMQ / Biomarkers

University of Texas at El Paso (USA) – Project: Biomarkers

 University of Witswatersrand, Perinatal HIV Research Unit (South Africa) – Projects: Superbooster therapy Paediatric HIV/TB

 University of Washington (USA) – Projects: Identify surrogate markers correlating with filarial worm levels to rapidly measure treatment effectiveness (filarial diseases)

University Sains Malaysia (USM) (Malaysia) – Projects: ASAQ / ASMQ

Uppsala University (Sweden) – Projects: Fexinidazole-Miltefosine combination / New treatments for HIV/VL / New treatments for PKDL / Miltefosine-Paromomycin combination for Africa

Utrecht University (The Netherlands) – Projects: Fexinidazole-Miltefosine combination / New treatments for HIV/VL co-infectionMiltefosine-Paromomycin combination for Africa

Various academic partners (South Africa, Kenya, Uganda, Tanzania) – Projects: ‘4-in-1’ LPV/r/ABC/3TC

top of the page

 

University “Spin-off”

Epichem (Australia) – Projects: Leish H2LChagas H2L / Fenarimol / Chagas C205 series / Leish L205 series

top of the page

 

Research Institutes

Bioaster (France) – Projects: Leish L205 Series / Chagas C205 series

Broad Institute, MIT and Harvard (USA) – Projects: Screening Chagas / Screening leishmaniasis

 Fundacion Para el Estudio de las Infecciones Parasitarias y enfermedad de Chagas (FIPEC) (Argentina) Projects: Clinical studies for Chagas disease.

Georges Institute for Global Health (Australia) – Projects: ASAQ

Ifakara Health Institute (Tanzania) – Projects: ASMQ / LPV/r pellets with dual NRTI

IMEA Consulting France: Institut de Médecine et d’Epidémiologie Appliquée, Département de Santé Tropicale (France) – Projects: ASAQ

 Institut Bouisson Bertrand (France) – Projects: advices for clinical trials development (filarial diseases) 

Institut de Recherche pour le Développement (IRD) (France) – Projects: Acoziborole / Fexinidazole (HAT) / Identify surrogate markers correlating with filarial worm levels to rapidly measure treatment effectiveness: Imaging technique Diffuse Reflectance Spectroscopy (DRSsr) & advice for clinical trials development (filarial diseases)

 Institut de Recherche pour le Développement (IRD) (Sénégal) – Projects: ASAQ

Institut National de Recherche Biomédicale (DRC) – Projects: Acoziborole / Fexinidazole (HAT) 

Institut Pasteur (France) – Projects: Screening

 Institut Pasteur Korea (South Korea) – Projects: Screening Chagas / Screening leishmaniasisLeish H2LChagas H2L / Fenarimol 

Institute of Tropical Medicine Antwerp (Belgium) – Projects: Acoziborole/ Fexinidazole (HAT) / New treatments for HIV/VL  / VL-0208 / New VL treatments Asia /  ‘4-in-1’ LPV/r/ABC/3TC

 Institute of Endemic Disease (IEND), Khartoum University (Sudan), Leishmaniasis East Africa Platform (LEAP) – Projects: VL-0208 / SSG&PM / Fexinidazole-Miltefosine combination / New treatments for PKDL / Fosravuconazole / Miltefosine-Paromomycin combination for Africa 

Instituto Nacional de Epidemiología Dr Fatala Cháben (Argentina) – Projects: Biomarkers / New benz regimens +/- fosravuconazole  / Paediatric dosage form of benznidazole

Instituto de Salud Carlos III (Spain) – Projects: New treatments for PKDL 

Kenya Medical Research Institute (Kenya) – Projects: Fexinidazole-Miltefosine combination / Miltefosine-Paromomycin combination for Africa / LPV/r pellets with dual NRTI / SSG&PM / ASAQ / ASMQ

KIT (Kononklijk Instituut voor de Tropen) Royal Tropical Institute (The Netherlands) – Projects: VL-0208 / Fexinidazole-Miltefosine combination

Kitasato Institute for Life Sciences (Japan) – Projects: Screening Chagas / Screening leishmaniasis

Leti, CEA (France) – Projects: Biomarkers / Identify surrogate markers correlating with filarial worm levels to rapidly measure treatment effectiveness: Imaging technique Diffuse Reflectance Spectroscopy (DRSsr) (filarial diseases)

Luxembourg Institute of Health (Luxembourg) – Projects: New benz regimens +/- fosravuconazole Fexinidazole (Chagas) / Acoziborole 

Medical Research Council (MRC) (UK) – Projects: ‘4-in-1’ LPV/r/ABC/3TC

National Institutes of Health (USA) – Projects: Screening filarial diseases / CpG-D35

Necker Institute (France) – Projects: ‘4-in-1’ LPV/r/ABC/3TC

Northwick Park Institute for Medical Research (UK) – Projects: Screening filarial diseases / Screening Chagas / Screening leishmaniasis / Macro Filaricide 3 / Oxfendazole

 Nyumbani Lea Toto Project, Children of God Relief Institute (COGRI) (Kenya): LPV/r pellets with dual NRTI

Rajendra Memorial Research Institute of Medical Sciences (RMRIMS) (India) – Projects: New treatments for PKDL / New VL treatments Asia / New treatments for HIV/VL 

Research Foundation for Tropical Diseases and the Environment (REFOTDE) (Cameroon) – Projects: Identify surrogate markers correlating with filarial worm levels to rapidly measure treatment effectiveness: Imaging technique Diffuse Reflectance Spectroscopy (DRSsr) (filarial diseases)

Shandukani Research Centre Wits Reproductive Health and HIV Institute (South Africa) – Projects: Superbooster therapy paediatric HIV/TB

The Netherlands Cancer Institute (The Netherlands) – Projects: Fexinidazole-Miltefosine combination / New treatments for HIV/VL / VL-0208 / New treatments for PKDL / Miltefosine-Paromomycin combination for Africa

The Swiss Tropical and Public Health Institute (Switzerland) – Projects: Screening Chagas / Screening leishmaniasis / Leish H2LChagas H2L / Acoziborole / Fexinidazole (HAT) / NECT / SSG&PM / LPV/r pellets with dual NRTI

University of Georgia Research Foundation (USA) – Projects: Biomarkers

University of Georgia, The Center for Tropical and Emerging Global Diseases (CTEGD) (USA) – Projects: Azoles E1224

Walter Reed Army Institute (USA) – Projects: Screening

top of the page

 

National Research Centres

Administración Nacional de Laboratorios e Institutos de Salud (ANLIS)Centro Nacional de Diagnóstico e Investigación de Endemo-epidemias (Argentina) – Projects: Paediatric dosage form of benznidazole 

B.P Koirala Institute of Health Sciences (Nepal) – Projects: Clinical trials for visceral leishmaniasis.

 Brazilian Biosciences National Laboratory (LNBio), Centro Nacional de Pesquisa em Energia e Materiais (CNPEM) (Brazil) – Projects: Screening Chagas / Screening leishmaniasis / Chagas H2L

 Centre National de Recherche et de Formation sur le Paludisme (CNRFP) (Burkina Faso) – Projects: ASMQ

 CSIR – Central Drug Reseach Institute (India) – Projects: VL-2098 / DNDi-0690

Erasmus Medical Centre (The Netherlands) – Projects: Fosravuconazole / epidemiological studies on filarial diseases

Fiocruz, Fundaçao Oswaldo Cruz (Brazil) – Projects: Azoles E1224

Indian Council of Medical Research (ICMR) (India) – Projects: New VL treatments Asia / ASAQ / ASMQ

 Instituto Rene Rachou, Fiocruz Minas (Brazil) – Projects: New VL treatments Asia / New VL treatments Latin America

International Centre for Diarrhoeal Disease Research (icddr,b) (Bangladesh) – Projects: New treatments for PKDL / New VL treatments Asia

IS Global, Centre de Recerca en Salut Internacional de Barcelona (CRESIB) (Spain) – Projects: Screening ChagasBiomarkers / New benz regimens +/- fosravuconazole / Fexinidazole (Chagas)Azoles E1224

Joint Clinical Research Centres (Uganda) – Projects: LPV/r pellets with dual NRTI

Kala Azar Medical Research Centre (India) – Projects: New treatments for PKDL / New VL treatments Asia

Mycetoma Research Centre, Soba University Hospital (Sudan) – Projects: Fosravuconazole

National Institute for Medical Research (NIMR) (Tanzania) – Projects: ASMQ

 National Institute of Pathology (India) – Projects: New treatments for PKDL

National Vector Borne Disease Control Programme (India) – Projects: New VL treatments Asia

Novartis Centre de la Recherche Santé Animale (Switzerland) – Projects: Screening filarial diseases

Seattle Institute for Biomedical and Clinical Research (SIBCR) (USA) – Projects: Discovery for NTDs.

Texas Biomedical Research Institute (USA) – Projects: Biomarkers

top of the page

 

NGOs/IOs

AEDES, the European Agency for Development and Health, consulting company for social and public health sector (Belgium) – Projects: ASAQ

 AWOL (UK) – Projects: ABBV-4083

Clinton Health Access Initiative (USA) – Projects: LPV/r pellets with dual NRTI / ‘4-in-1’ LPV/r/ABC/3TC

Collective of Applied Studies and Social Development (CEADES) (Bolivia) – Projects: Azoles E1224 / New benz regimens +/- fosravuconazole / Fexinidazole (Chagas)

Communauté Baptiste du Congo (CBCO) (Democratic Republic of Congo) – Projects: Fexinidazole (HAT)

Enhancing Care Foundation (ECF) (South Africa) – Projects: Superbooster therapy paediatric HIV/TB

Epicentre (France) – Projects: NECT / ASAQ / ASMQ

Epicentre Research Center (Uganda) – Projects: LPV/r pellets with dual NRTI

Family AIDS Care and Education Services (FACES) Project (Kenya) – Projects: LPV/r pellets with dual NRTI

Fundación Mundo Sano  (Argentina) – Projects: New benz regimens +/- fosravuconazole / Paediatric dosage form of benznidazole / Ravidasvir/Sofosbuvir

IDA Foundation (The Netherlands) – Projects: VL-0208 / SSG&PM

i+solutions (The Netherlands) – Projects: VL-0208 / SSG&PM / New treatments for PKDL

Institute of Microbial Chemistry(Japan) – Projects: Screening Chagas / Screening leishmaniasis

 Management and Development for Health (MDH) (Tanzania) – Projects: LPV/r pellets with dual NRTI

Médecins Sans Frontières – Projects: ASAQ  / NECT / Fexinidazole (HAT) / Fexinidazole-Miltefosine combination  / New treatments for HIV/VL  / VL-0208 / New VL treatments Asia / SSG&PM  / Generic Ambisome /  Biomarkers / Azoles E1224 / Fexinidazole (Chagas) / ‘4-in-1’ LPV/r/ABC/3TC / Ravidasvir/Sofosbuvir

 Offre Technique d’Etude et de Coopération Internationale (OTECI) (France) – Projects: ASMQ

Royal Society of Chemistry (UK): MoU to promote open source discovery.

Salvensis (UK) – Projects: Screening filarial diseases

UNITAID (Switzerland) – Projects: ‘4-in-1’ LPV/r/ABC/3TC / LPV/r pellets with dual NRTI

WHO-NTD (Neglected Tropical Diseases department) (Switzerland) – Projects: Fexinidazole (HAT) 

WHO-TDR, Special Programme for Research and Training in Tropical Diseases (Switzerland) – Projects: ASAQ / ASMQ / Screening Chagas / Screening leishmaniasis / New VL treatments Asia

top of the page

 

PDPs/PPPs

FIND, Foundation for Innovative New Diagnostics (Switzerland) – Projects: Collaboration and material transfer agreement to develop an ELISA-based diagnostic test for leishmaniasis. MoU for collaboration in the field of neglected tropical diseases.

 Lygature (formerly TI Pharma) (The Netherlands) – Projects: DNDi partner for discovery activities.

Medicines for Malaria Venture (MMV) (Switzerland) – Projects: Screening filarial diseases / ASAQ / ASMQ

Novartis Institute for Tropical Diseases (Singapore) – Projects: Lead optimization

 Institute for One World Health (OWH) (USA) – Projects: VL-0208 / New VL treatments Asia / SSG&PM

TB Alliance (USA) – Projects: NitroimidazoleSCYX-2035811 / VL-2098 /  Screening Chagas / Screening leishmaniasis DNDi-0690

top of the page

 

Hospitals

Academic Medical Center in Amsterdam (The Netherlands) – Projects: Miltefosine-Paromomycin combination for Africa

Amudat General Hospital (Uganda) – Projects: Fexinidazole-Miltefosine combination / SSG&PM / Miltefosine-Paromomycin combination for Africa

Arba Minch Hospital (Ethiopia) – Projects: SSG&PM

CHUV, Centre Hospitalier Universitaire Vaudois (Switzerland) – Projects: ASMQ

Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital (South Africa) – Projects: Superbooster therapy paediatric HIV/TB

Gertrude’s Children’s Hospital (Kenya) – Projects: LPV/r pellets with dual NRTI

Hospital Clinic de Barcelona (Spain) – Projects: Fexinidazole (Chagas)

Hospital de Niños de Jujuy (Argentina) – Projects: Paediatric dosage form of benznidazole 

Hospital de Niños Dr. Ricardo Gutiérrez (Argentina) – Projects: Paediatric dosage form of benznidazole / New benz regimens +/- fosravuconazole / Biomarkers

Hospital de Sant Joan Despí Moisès Broggi and Hosptial General de l’Hospitalet, Consorci Sanitari Integral (Spain) – Projects: Fexinidazole (Chagas)

Hospital General Universitari de Valencia (Spain) – Projects: New benz regimens +/- fosravuconazole / Fexinidazole (Chagas)

Hospital Independencia, Centro de Chagas y Patologia Regional (Argentina) – Projects: Paediatric dosage form of benznidazole / New benz regimens +/- fosravuconazole

 Hospital Kuala Lumpur (Malaysia) – Projects: Ravidasvir/Sofosbuvir

Hospital Público Materno Infantil (Argentina) – Projects: Paediatric dosage form of benznidazole

Hospital Sao José de Doencas Infecciosas (Brazil) – Projects: New VL treatments Latin America

 Kacheliba District Hospital (Kenya) – Projects: Fexinidazole-Miltefosine combination / Miltefosine-Paromomycin combination for Africa

 KATH, Komfo Anokye Teaching Hospital (Ghana) – Projects: ASAQ

 Kenyatta National Hospital (KNH) (Kenya) – Projects: LPV/r pellets with dual NRTI

Mbagathi District Hospital (Kenya) – Projects: LPV/r pellets with dual NRTI

Moi Teaching and Referral Hospital (Kenya) – Projects: LPV/r pellets with dual NRTI

 Muzaffarpur Hospital (India) – Projects: New treatments for PKDL

 National Museum of Natural History Paris (MNHN) (France) – Projects: Screening filarial diseases / Macro Filaricide 3 / Oxfendazole

Paediatric Hospital Joao Paulo II – FHEMIG (Brazil) – Projects: New VL treatments Latin America

Shaheed Suhrawardy Medical College and Hospital (Bangladesh) – Projects: New VL treatments Asia

SK Hospital Mymensingh (Bangladesh) – Projects: New treatments for PKDL

St. Lumumba Health Centre (Kenya) – Projects: LPV/r pellets with dual NRTI

Tygerberg Children’s Hospital (South Africa) – Projects: Superbooster therapy paediatric HIV/TB

 Vall d’Hebron University Hospital (Spain) – Projects: Fexinidazole (Chagas)

University Hospitals of Geneva (HUG) (Switzerland) – Projects: Biomarkers / Macro Filaricide 3 / Ravidasvir/Sofosbuvir

top of the page

 

Ministries of Health/Governmental Organizations

Gedarif MoH (Sudan). Leishmaniasis East Africa Platform (LEAP) – Projects: Various partnerships for clinical trials in the field of leishmaniasis / VL-0208 / SSG&PM

Bihar State Health Society (India) – Projects: New VL treatments Asia

Centre for Disease Control and Prevention CDC/President’s Emergency Plan for AIDS Relief (USA) – Projects: ‘4-in-1’ LPV/r/ABC/3TC

 Centro Nacional de Diagnostico e Investigacion de Endemo-epidemias (CeNDIE), Ministry of Health (Argentina) – Projects: Paediatric dosage form of benznidazole

Clinical Research Malaysia, Ministry of Health (Malaysia) – Projects: Ravidasvir/Sofosbuvir

Department of Health and Department of Science and Technology (South Africa) – Projects: Superbooster therapy paediatric HIV/TB

Department of Health South Africa (South Africa) – Projects: ‘4-in-1’ LPV/r/ABC/3TC / LPV/r pellets with dual NRTI

 Food & Drug Administration (FDA) (US) – Projects: CpG-D35

Ministry of Health, Leishmaniasis Control Programme (Brazil) – Projects: New VL treatments (Latin America)

 Ministry of Health, National Malaria Control Programme (Burundi) – Projects:  ASAQ

Ministry of Health (Cambodia) – Projects: ASMQ

Ministry of Health (DRC) – Projects: Various partnerships (financial and clinical trial agreement) in the field of HAT / NECT

Ministry of Health, Neglected Tropical Disease Directorate (Ethiopia) – Projects: SSG&PM / VL-0208 / Miltefosine-Paromomycin combination for Africa

Ministry of Health (Ghana) – Projects: ASAQ

Ministry of Health (Kenya) – Projects: LPV/r pellets with dual NRTI / SSG&PM / VL-0208 / Miltefosine-Paromomycin combination for Africa

Ministry of Health (Sierra Leone) – Projects: ASAQ

Ministry of Health, the Neglected Tropical Diseases Unit, Leishmaniasis Programme (Sudan) – Projects: New treatments for PKDL / SSG&PM / VL-0208 / Miltefosine-Paromomycin combination for Africa

Ministry of Health, Leishmaniasis Control Programme (Uganda) – Projects: SSG&PM / VL-0208

Ministry of Health and Family Welfare (Bangladesh) – Projects: New VL treatments Asia

Ministry of Health and Ministry of Industry, Science and Technology (Thailand) – Projects: Ravidasvir/Sofosbuvir

Ministry of Health, Province of Jujuy (Argentina) – Projects: Paediatric dosage form of benznidazole

National Control Programmes (DRC, Central African Republic, Guinea) – Projects: Fexinidazole (HAT)

National Trypanosomiasis Control Programme (DRC) – Projects: NECT / Acoziborole 

 Programa Nacional de Leishmaniasis (Colombia) – Projects: New CL combination therapies 

top of the page

 

Contract Research Organizations (CROs)

Accelera (Italy) – Projects: VL-2098 / DNDi-0690 / DNDi-6148 / Fexinidazole (HAT)

 Aesica (UK) – Projects: Acoziborole 

Amatsi Aquitaine (formerly Bertin Pharma) (France) – Projects: ASAQ / VL-2098Fexinidazole (HAT) / Acoziborole / CpG-D35

Analytical Services International (UK) – Projects: Emodepside

Aptuit (Italy) –  Projects: DNDi-0690 / Fexinidazole-Miltefosine combination for Africa / VL-2098 / Fexinidazole (HAT)

BaseCon (Denmark) – Projects: Fexinidazole-Miltefosine combination for Africa  / New treatments for HIV/VL / Fexinidazole (HAT) 

 Bioclinica (formerly CoreLab Partners) (France) – Projects: Azoles E1224

 Biotrial (France) – Projects: Fexinidazole (HAT)

Cardiabase (Banook Group) (France) – Projects: Fexinidazole-Miltefosine combination for Africa / Fexinidazole (HAT) / Acoziborole 

Calvert Labs (USA) – Projects: Pre-clinical phase for topical formulation against cutaneous leishmaniasis.

Cardinal Health (formerly Cardinal System) (France) – Projects: Azoles E1224

Catalent (USA) – Projects: Screening, discovery, clinical activities as well as registration and regulatory issues in the field of malaria.

Centipharm (Axynthis Group) (France) – Projects: CMC/manufacture of fexinidazole for HAT.

Central Diagnostics (India) – Projects: Partner in the field of visceral leishmaniasis.

Certara (formerly Quantitative Solutions) (USA) – Projects: Azoles E1224

 Charles River (formerly WIL Research) (France) – Projects: DNDi-6148 / Aminopyrazoles

Clinwin Research Services (Kenya) – Projects: ASMQ

Covance (UK) – Projects: VL-2098

Creapharm (France) – Projects: Fexinidazole (Chagas)

 Crystallise! (Switzerland) – Projects: DNDi-6148

 Doppel Pharma (Italy) – Projects: Ravidasvir/Sofosbuvir

Drugabilis (France) – Projects: Fexinidazole (HAT) / Acoziborole / Flubendazole Macrofilaricide / VL-2098

Endolytics (USA) – Projects: VL-2098

 Envigo (formerly Harlan Laboratories and Huntingdon Life Sciences Limited) (Switzerland) – Projects: Pre-clinical research agreement for Chagas disease / VL-2098

 Eurofins Advinus (formerly Advinus Therapeutics Ltd.) (India) – Projects: Acoziborole / VL-2098 / DNDi-0690 

 Eurofins CEREP (France) – Projects: Aminopyrazoles / Chagas C205 series / Leish L205 series

Eurofins Optimed (France) – Projects: Acoziborole / ‘4-in-1’ LPV/r/ABC/3TC / Fexinidazole (HAT) / DNDi-6148

 Eurofins Pharma Discovery Services (formerly Eurofins Panlabs) (USA) – Projects: Aminopyrazoles / Leish L205 series

 FP Clinical Pharma (Argentina) – Projects: New benz regimens +/- fosravuconazole

Frontage (USA) – Projects: Azoles E1224

GVK BIO (India) – Projects: Clinical phase for malaria and VL / New VL treatments Asia

Hammersmith Medicines Research (UK) – Projects: Emodepside

 Hypha Discovery (UK) – Projects: DNDi-0690

Instituto de Investigaciones en Ingeniería Genética y Biología Molecular “Dr. Héctor N. Torres”, National Council of Scientific and Technological Research (INGEBI-CONICET) (Argentina) – Projects: New benz regimens +/- fosravuconazole  / Fexinidazole (Chagas) / Biomarkers /  Azoles E1224 / Paediatric dosage form of benznidazole

JSS Medical Research (Canada) – Projects: Anfoleish / Fexinidazole (Chagas)

Lamba Therapeutics Research Ldt. (India) – Projects: New treatments for PKDL

LAT Research (Argentina) – Projects: Azoles E1224 / New benz regimens +/- fosravuconazole 

Nucleo de desenvolvimento farmacêutico e cosméticos  (NUDFAC) (Brazil) – Projects: Azoles E1224 / Paediatric dosage form of benznidazole / New benz regimens +/- fosravuconazole 

Niche Science and Technology (UK) – Projects: Emodepside

Patheon (UK) – Projects: Formulation development and manufacturing for HAT / Acoziborole

Penn Pharmaceuticals Services (UK) – Projects: Acoziborole / DNDi-0690

PhinC Development (France) – Projects: Fexinidazole (HAT) / Fexinidazole-Miltefosine combination for Africa / Acoziborole / New benz regimens +/- fosravuconazole

RCTs (France) – Projects: NECT / Fexinidazole (HAT) / Acoziborole

Roowin (France) – Projects: CMC activities for HAT.

Sandexis (UK) – Projects: Leish H2L / DNDi-5421 DNDi-5610 / Aminopyrazoles / CGH VL series 1 / Chagas H2L / DNDi-6148 / Oxachagas

Selcia (UK) Projects: VL-2098

Sigma-Aldrich (UK) – Projects: VL-2098

SGS (France) – Projects: Clinical study of fexinidazole for HAT, subsequently performing bioanalyses / Acoziborole / Fexinidazole (HAT)

SGS (Belgium) – Projects: Fexinidazole-Miltefosine combination for Africa / Fexinidazole (HAT)

 TCG Lifesciences (India) – Projects: Leish H2L / Chagas H2L

Theradis Pharma (France) – Projects: Fexinidazole (HAT) / Acoziborole

United BioSource Corporation (UBC) (Switzerland) – Projects: New treatments for HIV/VLFexinidazole-Miltefosine combination for Africa

WuXi AppTech (China) – Projects: ScreeningLeish H2L / DNDi-5421 DNDi-5610 / Aminopyrazoles / Oxachagas / Nitroimidazole / SCYX-2035811 / CGH VL series 1 / Chagas H2L / DNDi-6148 / DNDi-0690 / ‘4-in-1’ LPV/r/ABC/3TC / Chagas C205 series / Leish L205 series

top of the page

 

Platforms and Networks

HAT Platform – Projects: NECT / Fexinidazole (HAT) / Acoziborole

Leishmaniasis East Africa Platform (LEAP) – Projects: Fexinidazole-Miltefosine combination / New treatments for PKDL / New treatments for HIV/VL / SSG&PM / Fexinidazole-Miltefosine combination for Africa / VL-0208

NHEPACHA Network – Projects: Biomarkers

Platform of Integral Care for Patients with Chagas Disease (Bolivia) – Projects: New benz regimens +/- fosravuconazole / Fexinidazole (Chagas) / Azoles E1224

top of the page

 

 

Please contact us at partnership@dndi.org to propose collaborative projects.

top of the page